English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Methods   Seven English and Chinese databases were used to search for qualified experimental studies as of July 27, 2020. All data were extracted directly from the included studies, and no special conversion formula was used. The weighted mean difference (WMD), 95% confidence interval (CI), and odds ratio (OR) were used for evaluation.Results   Forty-two studies involving 3793 subjects met the qualification criteria. For common pneumonia, a short duration of flu-like symptoms (WMD = −1.81, 95% CI = −2.12 to −1.50,  P  < 0.001), sputum (WMD = −1.10, 95% CI = −1.50 to −0.70,  P  < 0.001), pulmonary rale (WMD = −2.03, 95% CI = −2.74 to −1.31,  P  < 0.001), pulmonary imaging improvement (WMD = −1.88, 95% CI = −2.28 to −1.47,  P  < 0.001), curative effect (OR = 3.65, 95% CI = 2.81 to 4.76,  P  < 0.001), and healing period (WMD = −1.68, 95% CI = −2.62 to −0.74,  P  < 0.001) were associated with the Lianhua Qingwen group; subgroup analysis based on flu-like symptoms showed statistically significant improvements in fever and cough. For COVID-19 pneumonia, improvements in flu-like symptoms (OR = 3.18, 95% CI = 2.36 to 4.29,  P  < 0.001), shortness of breath (OR = 10.62, 95% CI = 3.71 to 30.40,  P  < 0.001), curative effect (OR = 2.49, 95% CI = 1.76 to 3.53,  P  < 0.001), healing period (WMD = −2.06, 95% CI = −3.36 to −0.75,  P  = 0.002), and conversion of severe cases (OR = 0.46, 95% CI = 0.27 to 0.77,  P  = 0.003) were associated with the Lianhua Qingwen group; subgroup analysis indicated statistically significant improvements of fever, cough, fatigue, and muscle pain in the Lianhua Qingwen group compared to the conventional drug group. Regarding adverse reactions, no significant difference was detected for common pneumonia (OR = 0.75, 95% CI = 0.54 to 1.05,  P  = 0.097).Conclusions   Lianhua Qingwen combined with conventional drugs may be a promising therapy for treating common pneumonia and COVID-19 pneumonia.

Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis